€20m · Other round · Healthtech · Copenhagen, Denmark
Biograil has closed a €20m financing round backed by Verve Ventures and Megatrend Invest, with HTGF participating through its Opportunity growth fund. The Copenhagen biotech will use the capital to complete non-clinical GLP studies and establish a GMP manufacturing process ahead of planned Phase 1 testing of its BIONDD device, according to the company announcement.
A capsule has to deliver a device, not only a drug
Biograil is developing a small oral capsule for medicines that are usually injected. After the capsule dissolves in the stomach, a spring-loaded device attaches to the stomach wall and releases the active substance into tissue for systemic distribution. The company says the bio-compostable device then passes through the gastrointestinal tract.
That mechanism is intended to address a difficult drug-delivery problem. Large biological molecules are easily degraded in the digestive system and generally do not cross the gut wall efficiently. Biograil is therefore not trying to reformulate an injectable medicine as an ordinary tablet; it is building a physical route through the stomach lining while keeping the patient experience close to swallowing a conventional capsule.
The commercial value depends on repeatable manufacturing as much as biological performance. A device that contains moving parts, carries a drug and contacts stomach tissue has to be produced consistently under pharmaceutical quality controls. Funding GLP studies and a GMP process before the first human trial is what turns the platform from an engineering prototype into a candidate that drug partners can evaluate inside a regulated development programme.
Clinical preparation is the next de-risking step
Biograil was founded in 2019 and remains pre-clinical. Its investor syndicate includes pharmaceutical and materials groups alongside venture investors, while the company also refers to non-dilutive partnership funding. Those relationships can help match the platform with compounds that have valuable injectable markets or could not previously be delivered orally.
The new round does not complete that validation. It finances the studies, manufacturing controls and documentation needed to enter Phase 1, where Biograil will have to demonstrate that the device can be administered safely and deliver its payload predictably in people. The company says it expects a larger financing in 2027, making the current programme a defined bridge to the evidence required for that next raise.
Sources checked:
Biograil company announcement · Biograil technology page · EU-Startups reporting · Tech.eu Funding Explorer
